Sanofi and As­traZeneca's RSV an­ti­body cuts hos­pi­tal­iza­tions by 83% in late-stage study, as $10B mar­ket bat­tle heats up

Sanofi and As­traZeneca’s RSV an­ti­body nir­se­vimab cut the rate of hos­pi­tal­iza­tions by 83% in a Phase II­Ib tri­al, the French phar­ma gi­ant said Fri­day.

The study re­sults are the lat­est in a string of in­dus­try suc­cess­es against RSV, or res­pi­ra­to­ry syn­cy­tial virus. Ear­li­er this month, GSK won FDA ap­proval for the first-ever RSV vac­cine for old­er adults, and Pfiz­er has a sim­i­lar RSV shot await­ing an FDA de­ci­sion lat­er this month. All told, a range of phar­ma gi­ants are prepar­ing to soon launch RSV med­i­cines, which Wall Street an­a­lysts fore­cast will grow to a $10 bil­lion-plus mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER